Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

Regeneron Pharmaceuticals logo
$674.27 +10.41 (+1.57%)
Closing price 02/13/2025 04:00 PM Eastern
Extended Trading
$671.50 -2.77 (-0.41%)
As of 02/13/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Key Stats

Today's Range
$661.94
$677.69
50-Day Range
$663.86
$788.00
52-Week Range
$642.00
$1,211.20
Volume
604,705 shs
Average Volume
978,359 shs
Market Capitalization
$74.10 billion
P/E Ratio
17.61
Dividend Yield
N/A
Price Target
$973.13
Consensus Rating
Moderate Buy

Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

REGN MarketRank™: 

Regeneron Pharmaceuticals scored higher than 99% of companies evaluated by MarketBeat, and ranked 43rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Regeneron Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Regeneron Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Regeneron Pharmaceuticals are expected to grow by 21.63% in the coming year, from $36.67 to $44.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Regeneron Pharmaceuticals is 17.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.20.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Regeneron Pharmaceuticals is 17.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.10.

  • Price to Earnings Growth Ratio

    Regeneron Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Regeneron Pharmaceuticals has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Regeneron Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.99% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Regeneron Pharmaceuticals has recently increased by 3.30%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Regeneron Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Regeneron Pharmaceuticals does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Regeneron Pharmaceuticals is 2.30%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 1.97% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.

  • Read more about Regeneron Pharmaceuticals' dividend.
  • Percentage of Shares Shorted

    1.99% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Regeneron Pharmaceuticals has recently increased by 3.30%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Regeneron Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 66 news articles for Regeneron Pharmaceuticals this week, compared to 22 articles on an average week.
  • Search Interest

    44 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    29 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 81% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Regeneron Pharmaceuticals' insider trading history.
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Businessman giving money on dark background — Photo
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now (REGN)
These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.
Elon’s “New Gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
FMR LLC Reduces Stake in Regeneron Pharmaceuticals Inc
See More Headlines

REGN Stock Analysis - Frequently Asked Questions

Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of the year. Since then, REGN stock has decreased by 5.3% and is now trading at $674.27.
View the best growth stocks for 2025 here
.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Tuesday, February, 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year.
Read the conference call transcript
.

Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others.

Regeneron Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (8.45%), FMR LLC (7.46%), Geode Capital Management LLC (2.21%) and Dodge & Cox (2.11%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles and George L Sing.
View institutional ownership trends
.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
2/04/2025
Today
2/14/2025
Ex-Dividend for 3/20 Dividend
2/20/2025
Dividend Payable
3/20/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$973.13
High Stock Price Target
$1,300.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+44.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
25 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
33.66%

Debt

Sales & Book Value

Annual Sales
$14.20 billion
Cash Flow
$42.46 per share
Book Value
$267.12 per share

Miscellaneous

Free Float
101,670,000
Market Cap
$74.10 billion
Optionable
Optionable
Beta
0.08

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:REGN) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners